ArticlemedRxiv : the preprint server for health sciences2025
Utilizing virus genomic surveillance to predict vaccine effectiveness.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
Abstract
As new vaccines are being developed for fast-evolving viruses, determining when and how to update them, and what data should inform these decisions, remains a significant challenge. We developed a model to inform these vaccine updates in near real-time and applied it to SARS-CoV-2 by quantifying the relationship between vaccine effectiveness (VE) and genetic distance from mRNA vaccine formulation sequences using 10,156 genomes from Connecticut (April 2021-July 2024) and data from over one million controls, employing a two-stage statistical approach. We showed a strong inverse correlation between spike gene amino acid distance and VE; every 10 amino acid substitutions away from the vaccine sequences resulted in a 15.4% (95% credible intervals (CrI): -2.0%, 34.6%) reduction in VE. Notably, this framework allows us to quantify the anticipated impact of emerging variants on VE, as demonstrated by the predicted 43.4% (95% CrI: -5.7%, 90.1%) drop in VE for the 2023/24 vaccine following the emergence of JN.1 variants based on sequence data alone. By linking amino acid substitutions to VE, this approach leverages genomic surveillance to monitor population-level protection and inform timely vaccine updates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.